Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
Cancer Vaccines01:30

Cancer Vaccines

337
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
337
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Asymptomatic Pembrolizumab-Associated Hypertriglyceridemia.

Cureus·2026
Same author

Current and emerging therapies targeting cell surface antigens and epigenetics in extensive stage small cell lung cancer: primer for clinicians.

Therapeutic advances in medical oncology·2026
Same author

EZH1/2 inhibition improves immunotherapy response through MHC Class II de-repression and neutrophil reprogramming.

bioRxiv : the preprint server for biology·2026
Same author

Timing of insertable cardiac monitor implantation after embolic stroke of undetermined source and its impact on atrial fibrillation detection: A target trial emulation analysis.

International journal of stroke : official journal of the International Stroke Society·2026
Same author

Mental Health Needs of Families of Patients in Intensive Care Units and the Role of Mobile Health: Survey Study.

JMIR formative research·2026
Same author

Atrial fibrillation detection after embolic stroke of undetermined source: Development and validation of the CATCH-AF score.

International journal of stroke : official journal of the International Stroke Society·2026

相关实验视频

Updated: Jun 3, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

针对SCLC的免疫疗法的新进展

Tsering Dolkar1, Christopher Gates2, Zhonglin Hao3

  • 1Hospital Medicine, University of Kentucky, Lexington, Kentucky, USA.

Journal for immunotherapy of cancer
|January 6, 2025
PubMed
概括

小细胞肺癌 (SCLC) 显示初始治疗反应,但迅速复发. 针对DLL3的新兴免疫疗法,如双特异性T细胞参与剂和CAR-T细胞,为患有这种侵袭性神经内分泌瘤的患者提供了新的希望.

关键词:
双特异性T细胞参与者 - BiTE免疫治疗是一种免疫疗法.肺癌 肺癌 是 一种 肺癌.

更多相关视频

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

639
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

相关实验视频

Last Updated: Jun 3, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

639
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.8K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 神经内分泌新生体的神经内分泌新生体

背景情况:

  • 小细胞肺癌 (SCLC) 是一种具有攻击性的神经内分泌癌症,其特点是最初的治疗敏感性,随后是快速复发和治疗耐药性.
  • 虽然SCLC中遗传突变很罕见,但DLL3受体的表达很高,为新疗法提供了一个有前途的标.

研究的目的:

  • 审查针对DLL3受体的小细胞肺癌新兴免疫治疗策略.
  • 突出两种特异性T细胞参与剂,CAR-T细胞和抗体-药物合物在克服SCLC治疗折射性的潜力.

主要方法:

  • 对SCLC中DLL3向免疫疗法的当前临床试验数据的审查.
  • 对双特异性T细胞参与剂的早期II期和III期试验结果的分析.
  • 目前正在进行的第一次人类CAR-T细胞SCLC试验的概述.

主要成果:

  • 针对DLL3的双特异性T细胞参与剂在正在进行的II期和III期临床试验中显示出有前途的结果.
  • 目前正在进行对SCLC的CAR-T细胞疗法的早期临床研究.

结论:

  • 针对DLL3的免疫疗法代表了SCLC治疗的重大进步,有可能改善患者的治疗结果.
  • 双特异性T细胞参与者和CAR-T细胞的发展显示出对管理这种具有挑战性的恶性瘤有相当大的希望.